Chronic Hepatitis C Clinical Trial
Official title:
Combination of Alpha Interferon With Long Term Ribavirin Therapy for Patients With Chronic Hepatitis C
Hepatitis C is a major cause of liver disease in the United States and leads to cirrhosis of
the liver in approximately one-third of patients some of whom will ultimately suffer from
liver failure or liver cancer. At present, the recommended therapy of hepatitis C is the
combination of alpha interferon and ribavirin given for 6 to 12 months. Ribavirin is a
antiviral drug that is given by mouth. Interferon is both an antiviral and an immune
medication which must be given by injections (three times a week) and has many difficult
side effects. The purpose of this study is to determine whether the combination of ribavirin
and interferon improve the liver disease of hepatitis C and whether improvements can be
maintained by continuing ribavirin therapy long-term. This study will take 100 to 120
patients suffering from hepatitis C and place them under combination drug therapy with alpha
interferon and ribavirin. The course of drug therapy is scheduled to last 6 to 12 months.
Patients will be selected after appropriate screening for hepatitis C virus and elevated
liver enzymes are conducted and liver biopsy shows chronic hepatitis with some degree of
injury and scarring.
During the first 6 months of the study, subjects will be asked to return to the outpatient
clinic for routine check-ups and blood tests every 2 to 4 weeks. Blood tests will include
tests for hepatitis C virus. If the virus test becomes negative on treatment, the therapy
will be considered successful and will be continued for a full 6 or 12 months (depending
upon the strain of virus).
If the virus test does not become negative during the first six months of treatment,
subjects will be considered "non-responders" and will stop taking interferon but will
continue on ribavirin alone or an identically appearing placebo tablet. These non-responsive
subjects will continue this therapy for an additional 12 months. (A year-and-a-half total).
Upon completion of the drug therapies, subjects will be requested to submit blood samples
and undergo a liver biopsy to determine if the therapy was successful. Test results that
reveal a loss of hepatitis C antibodies or normal levels of liver enzymes will be deemed
successful.
Patients that have successful laboratory test results will be considered for continuation of
ribavirin therapy. Patients that received placebo for a year will be eligible to receive
ribavirin long-term at the end of the study.
Status | Completed |
Enrollment | 120 |
Est. completion date | September 2002 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Both |
Age group | N/A and older |
Eligibility |
INCLUSION CRITERIA: Age above 18 years, male or female. Serum alanine or asparate aminotransferase activities that are above the upper limit of normal (ALT greater than 41 or AST greater than 31 U/L) on an average of three determinations taken during the previous 6 months. The mean of the three determinations will be defined as "baseline" levels. Presence of anti-HCV and HCV RNA in serum tested at least once during the previous six months. Evidence of chronic hepatitis on liver biopsy done within the previous 12 months with a histology activity index of at least 6 (out of a maximum of 22). Written informed consent. EXCLUSION CRITERIA: If previously treated with interferon or ribavirin, must not have a lack of sustained virological response as shown by the presence of HCV RNA in serum six months after stopping therapy. Patients must not have received the combination of alpha interferon and ribavirin in the past. Decompensated liver disease, as marked by bilirubin greater than 4 mg%, albumin less than 3.0 gm%, prothrombin time greater than 2 sec prolonged, or history of bleeding esophageal varices, ascites or hepatic encephalopathy. Patients with ALT levels greater than 1000 U/L (greater than 25 times ULN) will not be enrolled but may be followed until three determinations are below this level. Pregnancy or, in women of child-bearing potential or spouses of such women, inability to practice adequate contraception, defined as vasectomy in men, tubal ligation in women, or use of condoms and spermacide, or birth control pills, or an intrauterine device. Significant systemic or major illnesses other than liver disease, including congestive heart failure, renal failure (creatinine clearance less than 50 ml/min), organ transplantation, serious psychiatric disease or depression, and angina pectoris. Pre-existing anemia (hematocrit less than 36% for men and less than 34% for women) or known history of hemolytic anemia. Antiviral or immunosuppressive therapy within the last 6 months. Evidence of another form of liver disease in addition to viral hepatitis (e.g., autoimmune liver disease, Wilson's disease, alcoholic liver disease, hemochromatosis, alpha-1-antitrypsin deficiency). Any evidence of coronary artery disease or cerebral vascular disease, including abnormalities on exercise stress testing in patients with defined risk factors who will be screened for evidence of underlying coronary artery disease. Active substance abuse, such as alcohol, inhaled or injection drugs within the previous one year. Evidence of hepatocellular carcinoma; either alphafetoprotein (AFP) levels greater than 50 ng/ml (normal is less than 9 ng/ml) and /or ultrasound (or other imaging study) demonstrating a mass suggestive of liver cancer. Clinical gout. |
Endpoint Classification: Efficacy Study, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
United States,
Alter HJ. Descartes before the horse: I clone, therefore I am: the hepatitis C virus in current perspective. Ann Intern Med. 1991 Oct 15;115(8):644-9. Review. — View Citation
Kiyosawa K, Sodeyama T, Tanaka E, Gibo Y, Yoshizawa K, Nakano Y, Furuta S, Akahane Y, Nishioka K, Purcell RH, et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology. 1990 Oct;12(4 Pt 1):671-5. — View Citation
Major ME, Feinstone SM. The molecular virology of hepatitis C. Hepatology. 1997 Jun;25(6):1527-38. Review. — View Citation
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01937975 -
The Pharmacokinetics of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Participants With Renal Insufficiency (MK-5172-050)
|
Phase 1 | |
Completed |
NCT03673696 -
The Tolerability and Pharmacokinetics Study of HEC74647PA Capsule in Healthy Adult Subjects
|
Phase 1 | |
Completed |
NCT02250001 -
Asunaprevir/Daclatasvir Safety Surveillance in Japanese Patients With Chronic Hepatitis C
|
N/A | |
Completed |
NCT03088917 -
'Fibrosis in the Lost Hepatitis C Population - Track, Trace and Treat'
|
||
Completed |
NCT02207088 -
Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease
|
Phase 3 | |
Not yet recruiting |
NCT02865369 -
Regression of Liver Fibrosis After Daclatasvir and Asunaprevir Treatment
|
N/A | |
Recruiting |
NCT02638233 -
Therapy With Ledipasvir/Sofosbuvir in Patients With Genotype 1 HCV Infection Receiving Opiate Substitution Therapy
|
Phase 4 | |
Not yet recruiting |
NCT02511496 -
Status of Chronic Liver Disease in Hepatitis C Virus (HCV) Patients Coinfected With Human Immunodeficiency Virus (HIV) in Andalusia
|
N/A | |
Completed |
NCT02788682 -
Association of Vitamin D Binding Protein Polymorphisms With Response to HCV Therapy
|
N/A | |
Not yet recruiting |
NCT01949168 -
A Pilot Study of Boceprevir for the Treatment of Genotype 6 HCV
|
Phase 2 | |
Completed |
NCT01439776 -
Add Vitamin D With Standard of Care for Chronic Hepatitis C Patients
|
Phase 4 | |
Recruiting |
NCT01360879 -
Assessment of Liver FIBROsis by Real-time Tissue ELASTography in Chronic Liver Disease
|
N/A | |
Recruiting |
NCT01360892 -
Prediction of Incidence of Liver Cancer by Use of Real-time Tissue Elastography
|
N/A | |
Completed |
NCT00968357 -
Proof-of-concept Study to Evaluate the Safety and Immunomodulatory Effects of SCV 07 as Monotherapy or in Combination With Ribavirin in Noncirrhotic Subjects With Chronic Hepatitis C Who Have Relapsed
|
Phase 2 | |
Terminated |
NCT00962936 -
Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Chronic Hepatitis C Genotype I Infection
|
Phase 1/Phase 2 | |
Recruiting |
NCT01178749 -
Exploration of Chronic Hepatitis C Infection Receiving 24-week Interferon-α With Ribavirin Treatments
|
N/A | |
Recruiting |
NCT00575627 -
Pegylated-Interferon and Ribavirin in Hepatitis C Patients With Persistently Normal Alanine Aminotransferase Levels
|
Phase 4 | |
Completed |
NCT00537407 -
A Study of Debio 025 in Combination With PegIFN Alpha-2a and Ribavirin in Chronic HCV Patients Non-responders to Standard Treatment
|
Phase 2 | |
Recruiting |
NCT00370617 -
Pegylated-Interferon and Ribavirin Plus Metformin in the Treatment of Chronic HCV Infection and Insulin Resistance
|
Phase 4 | |
Completed |
NCT01684787 -
Study to Evaluate the Treatment for Chronic Hepatitis C With Normal Transaminases in HIV Positive Patients
|
Phase 4 |